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In nearly two years under the global health crisis of the Covid-19 pandemic, ethical 
issues regarding health data have been emerging quickly to the central focus of the 
global scientific community. Many papers have been retracted because of data problems, 
including those from top prestigious journals. For example, two papers on The Lancet 
and New England Journal of Medicine (NEJM) were retracted due to concerns regarding 
the veracity of datasets (Ledford & Van Noorden, 2020). Elisabeth Bik, an academic 
image sleuth, has found that 4% of more than 20000 biomedical papers she checked 
contained problematic image duplications; and her efforts have led to at least 172 
retractions (Shen, 2020). When the lives and well-being of countless people are at stake, 
and all eyes are on science, such mistakes could be (and have been) disruptive toward 
public trust, which might further fuel conspiracy theories and science-denying attitudes 
(Ball & Maxmen, 2020). We require health data of good ethical standards, but who will 
be responsible if such standards are not met? 
At first glance, the authors of the studies should be responsible for academic integrity 
since they are the ones who conduct the data collection and analysis. Ethical violations 
can be categorized into two groups: intentional and unintentional fraud. In the cases of 
intentional fraud, it is obvious that the articles should be retracted, and the authors 
should be punished for their misconducts, such as removal from professional positions. 
For example, anesthesiologist Joachim Boldt had fabricated data and committed other 
ethical violations, which led to nearly 90 retractions upon investigation and himself 
stripped of the professorship (Brainard & You, 2018). 
However, when the ethical violations are done unintentionally, and retractions only help 
improve scientific transparency (Vuong, 2020), who else besides the authors need to be 
held responsible? Firstly, it is the journal – or to be precise, all those involved in the 
publishing process (editors and reviewers). Academic journals, especially the top 
prestigious ones, often proudly present their claims for high-quality articles, which, in 
theory, have all gone through vigorous cross-checking procedures. As stated by the 
NEJM that “each published NEJM manuscript benefits from hundreds of hours of work by 
editors, statistical experts, manuscript editors, illustrators, proofreaders, and production 
personnel, who work to ensure that every paper meets exacting standards” it is clear 
that a publication is a product of various experts’ involvement besides the authors – thus, 
they should all be held accountable for the publication’s errors.  
Secondly, the ethical committees with the role of guaranteeing the studies being done 
ethically as well as funders providing financial and material support also have the 
responsibility of pre-assessing whether the registered studies’ methodology is compliant 
with ethical codes.   
In a recent well-known incident, a controversial paper suggesting the usage of 
hydroxychloroquine as an effective Covid-19 treatment was published in the 
International Journal of Antimicrobial Agents. One of its co-authors – Didier Raoult – is 
that journal’s editor-in-chief (Marcus, 2020). Donald Trump (former President of the 
United States) and Jair Bolsonaro (President of Brazil) endorsed the paper’s findings and 
encouraged the use of hydroxychloroquine. However, the review of Rosendaal (2020), a 
part of the review commissioned by the International Society of Antimicrobial 
Chemotherapy (ISAC), indicated that “this study suffers from major methodological 
shortcomings which make it nearly if not completely uninformative.” Indeed, the World 
Health Organization (WHO) strongly recommends against using hydroxychloroquine for 
Covid-19 treatment because it has little or no effect and may increase the risk of 
diarrhea, nausea, abdominal pain, drowsiness, and headache (World Health 
Organization, 2021). Given the “methodological shortcomings”, including data collection 
and analysis design, it is obscure why this study was supported by the French 
Government and ethically approved by the French Ethics Committee (CPP Ile de France) 
in the first place (Gautret et al., 2020). 
Some studies’ data are not collected by the authors but provided by external parties 
(such as data-vending companies). For instance, the Surgical Outcomes Collaborative 
(Surgisphere Corporation, Chicago, IL, USA) was the external company that supplied 
data for the two retracted papers on The Lancet and NJEM (Ledford & Van Noorden, 
2020). In both papers, the authors stated, “the data collection and analyses are deemed 
exempt from ethics review” as a result of using Surgisphere’s data (Mehra, Desai, Kuy, 
Henry, & Patel, 2020; Mehra, Desai, Ruschitzka, & Patel, 2020). Nevertheless, when the 
veracity of the data and analyses were concerned, the authors could not access the raw 
data and determined to retract the studies. Therefore, it is crucial to raise the question: 
“should scientists put the research integrity of health data in the hands of commercial 
companies?” 
Normally, after the ethical violations have been acknowledged, the articles are retracted, 
and the authors are disciplined by affiliated institutions and corresponding organizations. 
However, what would happen in cases where ethical standards are violated directly by 
the governments? During the Covid-19 pandemic, many countries, including Israeli, 
South Korea, and Taiwan, used digital technology to collect personal information for 
enhancing contact tracing and monitoring without consent (Mello & Wang, 2020). In 
Vietnam, the government sticks a label announcing Covid infected cases in front of 
patients’ houses without acquiring their permission. The national television broadcaster 
of Vietnam also filmed Covid-19 patients while they were on the edge of death without 
any face-concealing measures and broadcasted the records nationwide without their 
consent (Điểu, 2021). These activities indeed violate the World Medical Organization’s 
international code of ethics “to respect a patient’s right to confidentiality”.  
Some scholars argue that “sometimes it is unethical not to use available data” (Hand, 
2018). Fairly speaking, during the pandemic, the government sometimes needs to 
quickly arrive at important decisions that require compromises in one way or another. 
However, how can we justify governments breaching ethical codes or using data without 
consent when facing imminent threats? When a study is deemed to violate data ethics, 
external parties such as independent ethics review boards will be in charge of auditing 
the matter. In the case of the government, who will take on that role? 
Evidence-based policymaking is one of the most important implications of health 
research because it bridges practical impacts and insights derived from studies. The 
government’s attitude toward health data ethics can greatly influence the attitude of 
scientists in health research disciplines. If scientists perceive that their efforts to uphold 
academic integrity are meaningless in the face of nation-scale violations (Vuong, 2018), 
the ethical standards within the scientific community would be undermined. For these 
reasons, even though we have yet got answers to the questions posed above, we 
advocate that the issue of health data ethics should no longer be considered on the level 
of individual scientists or research labs, but rather as a problem involving all 
stakeholders, from publishers, funders, ethical committees to governments, for the sake 
of research integrity.  
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